GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.
The drug class continues to grow in popularity and raise questions in medtech around just how large its impact could be.
Positive clinical results for GLP-1s led to recent negative market movement for a few of the biggest names in diabetes technology. Analysts reacted by cutting some forecasts on sales to reflect increased pressure thanks to the GLP-1 updates. Insulet and Embecta noted the drug’s impact in their most recent quarterly earnings. GLP-1s even had an impact on Intuitive Surgical and its surgical robot for bariatric procedures.
Despite the cautious reaction during the companies’ quarterly earnings, analysts have recently tempered concerns around the drug class and its impact on diabetes technology.
Abbott now has data to back up this notion, too. The company sees GLP-1s as a potential modest accelerator for its FreeStyle Libre CGM product family.
Get the full story at our sister site, Drug Delivery Business News.